Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
In this study, I found up-regulation of aldo-keto reductase (AKR) 1B10, an enzyme that detoxifies lipid-derived reactive aldehydes, by development of cisplatin (CDDP)-resistance in lung cancer cells. In addition, the treatment with CDDP enhanced the nitric oxide production, which may participate in mechanism of the AKR1B10 induction. Furthermore, pretreating with AKR1B10 inhibitor overcame the CDDP resistance, suggesting the availability of the inhibitor in adjuvant therapy for CDDP treatment of lung cancer.
|